SCHEMBL8158326

SCHEMBL8158326

CCCCCCCCCCCCC(=S)Nc1ccc(C(F)(F)F)cc1OCCCC(=O)O

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PTGDR2 Q9Y5Y4 1/20 0.44
TRPV1 Q8NER1 4/20 0.44
PLK1 P53350 1/20 0.43
MGLL Q99685 1/20 0.42
HTT P42858 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
S1PR1 P21453 2/20 0.41
KDM4E B2RXH2 2/20 0.40
KMT2A Q03164 1/20 0.40
TLR2 O60603 2/20 0.39
TLR1 Q15399 2/20 0.39
PPARG P37231 2/20 0.39
PPARD Q03181 2/20 0.39
PPARA Q07869 2/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8162170 0.86 TSHR (0.53) ALDH1A1PLK1KDM4EKMT2A
SCHEMBL8156613 0.83 HDAC1 (0.52) ALDH1A1SMN1; SMN2MGLLHTTKDM4E
SCHEMBL8158408 0.81 ALDH1A1 (0.53) ALDH1A1CYP2C19KMT2A
SCHEMBL8150254 0.81 ALDH1A1 (0.53) ALDH1A1CYP2C19KMT2A
SCHEMBL8156126 0.81 ALDH1A1 (0.53) ALDH1A1CYP2C19KMT2A
SCHEMBL8151178 0.79 PTPN1 (0.54) ALDH1A1CYP2C19KMT2APPARG
SCHEMBL8156064 0.79 PTPN1 (0.54) ALDH1A1CYP2C19KMT2APPARG
SCHEMBL8158324 0.78 HDAC1 (0.45) ALDH1A1SMN1; SMN2MGLLHTTCYP1A2
SCHEMBL8157553 0.78 GAA (0.56) ALDH1A1PLK1KDM4EKMT2APPARG
SCHEMBL8158316 0.76 L3MBTL1 (0.41) ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6046183-A SYNERGISTIC MIXTURE OF FINASTERIDE AND DOXAZOSIN MERCK & CO., INC. (US) 2000-04-04 US disclosed
US-5994362-A ADMINISTERING FINASTERIDE AND CASODEX MERCK & CO., INC. (US) 1999-11-30 US disclosed
US-5753641-A SYNERGISTIC THERAPY COMPRISING FINASTERIDE AND TERAZOSIN DRUGS MERCK & CO., INC. (US) 1998-05-19 US disclosed
EP-0576603-A1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN MERCK & CO. INC. (US) 1994-01-05 EP disclosed
EP-0525885-A1 New sulphur containing nonsteroidal drugs as 5-alpha reductase inhibitors MERCK & CO. INC. (US) 1993-02-03 EP disclosed
WO-1992018132-A1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR MERCK & CO., INC. (US) 1992-10-29 WO disclosed
WO-1992016213-A1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN MERCK & CO., INC. (US) 1992-10-01 WO disclosed
WO-1992016233-A1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN MERCK & CO., INC. (US) 1992-10-01 WO disclosed